Ianalumab, an Antibody, Eases Sjögren’s Symptoms at High Dose in Trial

Ianalumab, an Antibody, Eases Sjögren’s Symptoms at High Dose in Trial

311540

Ianalumab, an Antibody, Eases Sjögren’s Symptoms at High Dose in Trial

Ianalumab (VAY736), an investigational antibody to treat Sjögren’s syndrome, at high dose was well-tolerated by patients using it for one year, and led to reductions in disease activity and significantly greater saliva production, data from a Phase 2b clinical trial show. Findings were shared at the 2021 American College of Rheumatology Convergence meeting, which took place virtually on Nov. 3–9, in the presentation, “Ianalumab (VAY736) Safety and Efficacy in Patients with Sjogren’s Syndrome: 52 Week Results from…

You must be logged in to read/download the full post.